Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01, FiscalAI reports. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 57.92%. The business had revenue of $0.61 million for the quarter, compared to the consensus estimate of $6.35 million.
Voyager Therapeutics Stock Down 8.0%
Shares of VYGR stock traded down $0.15 during trading hours on Thursday, reaching $1.72. 1,302,634 shares of the company’s stock were exchanged, compared to its average volume of 666,221. Voyager Therapeutics has a fifty-two week low of $1.68 and a fifty-two week high of $5.48. The stock has a market capitalization of $105.98 million, a P/E ratio of -0.96 and a beta of 1.20. The business has a fifty day moving average price of $2.61 and a 200-day moving average price of $3.43.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday, August 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.
Get Our Latest Stock Report on Voyager Therapeutics
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.
Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.
Further Reading
- Five stocks we like better than Voyager Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
